Physician profile
Yin Powers
NPI 1164187597
$4,816.58
in general payments reported to CMS, 2019-2025
19 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,705 · 2023: $1,297 · 2024: $739 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,098 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,098.04 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,275.62 | 2022-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $1,081.15 | 2022-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $471.61 | 2022-2023 | Mounjaro |
| Gilead Sciences, INC. | $346.11 | 2022-2023 | Vemlidy |
| Phathom Pharmaceuticals, INC. | $343.65 | 2024-2025 | Voquezna |
| Abbvie INC. | $309.08 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $140.20 | 2022 | |
| Glaxosmithkline, LLC. | $134.17 | 2023-2024 | Arexvy, Shingrix |
| Ibsa Pharma INC. | $128.61 | 2022-2023 | Tirosint, Licart |
| Sumitomo Pharma America, INC. | $117.63 | 2024-2025 | Gemtesa |
| Ardelyx, INC. | $100.38 | 2024-2025 | Ibsrela |
| Pfizer INC. | $87.93 | 2023 | |
| Agile Therapeutics, INC. | $85.39 | 2024 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $68.60 | 2023-2025 | |
| Radius Health, INC. | $37.12 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.93 | 2022-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $22.25 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.21 | 2025 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $13.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yin Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.